Explore the categories so you can find more about your search.
Categorie > Multiple Sclerosis
Guide To Multiple Sclerosis Launches On New European Health Website
Categorie : Multiple SclerosisIMR International Limited, developers of e-communication and clinical information solutions, announced the launch of a comprehensive guide to Multiple Sclerosis (MS) within its new public health portal; http://www.epgpatientdirect.org. Supported by Merck Serono, the [click link for full article ...
read more 
Sun Oct 2007
Peptimmune Initiates Phase I Study With A Novel Peptide Copolymer For The Treatment Of Multiple Sclerosis
Categorie : Multiple SclerosisPeptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and ...
read more Sun Oct 2007
Early Research Into A Treatment For Progressive MS, Scotland
Categorie : Multiple SclerosisScientists in Scotland may be on the way to discovering the cause of long term disability in people with multiple sclerosis (MS). New research carried out at the University of Aberdeen in Scotland, led by Professor Chris Linington, showed that some people with MS have specific antibodies (a type of ...
read more Sun Oct 2007
Genzyme And Bayer Schering Pharma AG, Germany Announce Start Of Phase 3 Program With Alemtuzumab For Treatment Of Multiple Sclerosis
Categorie : Multiple SclerosisGenzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS). [click link for full article] ...
read more Sun Oct 2007
Interferon Beta-1a Offers A Near 3-fold Improvement In Injection Tolerability Compared With The Original Formulation - 2-Year Phase IIIb Data
Categorie : Multiple SclerosisMerck Serono, a division of Merck KGaA, announced today new results of a two year (96 week) Phase IIIb study in 260 patients which has shown that the new formulation of Rebif® (interferon beta-1a) offers a near three-fold improvement in injection tolerability for patients with relapsing ...
read more Sun Oct 2007
Scientists ID Genes Affecting MS Patient Response To Copaxone
Categorie : Multiple SclerosisA group of Israeli scientists from the Technion Israel Institute of Technology, the Weizmann Institute of Science, and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis (MS) patients to the drug Copaxone®. These findin ...
read more Sun Oct 2007
New Drug Offers Potential For Restoration Of Lost Function In MS Patients
Categorie : Multiple SclerosisAccentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 rando ...
read more Sun Oct 2007
MS Society Adverts Make The BBC, UK
Categorie : Multiple SclerosisSeveral of the stars of the MS Society's new advertising campaign have appeared in a major feature on the BBC's website. The BBC feature includes an interview with Faye Roe who stars in the 'couple' advert with her husband, Matthew. Faye explains the impact MS has had on her own life and also talks ...
read more Sun Oct 2007
Multiple Sclerosis Nerve Damage Repaired By Scientists
Categorie : Multiple SclerosisNerve damage which was caused by multiple sclerosis (MS) was repaired by scientists from the Mayo Clinic, Rochester, USA, who were working with mice. The scientists said it is hoped this may lead the way to new treatments for humans. The immune system of a MS patient attacks the fatty myelin sheath ...
read more Sun Oct 2007
Smoking Has No Effect On Progression Of Multiple Sclerosis
Categorie : Multiple SclerosisContrary to an earlier report, smoking appears to have no effect on the progression of multiple sclerosis (MS), according to a study published in the October 9, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers in the Netherlands surveyed 364 peopl ...
read more Sun Oct 2007
Betaferon® Treatment Delays Disability In Early MS; Strong Efficacy Not Affected By Neutralizing Antibodies
Categorie : Multiple SclerosisBetaferon® (interferon beta-1b) significantly delays the development of confirmed disability progression and the development of clinically definite multiple sclerosis (MS) in patients who are treated shortly after their first clinical MS event or "attack". The presence of neutralizing antib ...
read more Sun Oct 2007
FTY720 May Repair Or Reduce Damage Caused By Multiple Sclerosis Through A Direct Effect In The Brain
Categorie : Multiple SclerosisNew preclinical data presented at European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague suggests that FTY720 (fingolimod) directly reduces neurodegeneration and enhances repair of the central nervous system (CNS) damage caused by multiple sclerosis (MS) by interacti ...
read more Sun Oct 2007
MS Treatment With AVONEX For 2 Years Reduces Probability Of Reaching More Severe Disability Milestones At 8 Years
Categorie : Multiple SclerosisA post-hoc analysis from a Phase III clinical trial of AVONEX ® (interferon beta-1a) and post-randomization eight-year follow up shows that six-month sustained progression of disability at two years, using the Expanded Disability Status Scale (EDSS), is a significant predict ...
read more Sun Oct 2007
New Data Suggests Progression Of Disability At Two Years Predicts Multiple Sclerosis (MS) Disability Progression At Eight Years
Categorie : Multiple SclerosisA post-hoc analysis from a Phase III clinical trial of AVONEX(R) (interferon beta-1a) and post-randomization eight-year follow up shows that six-month sustained progression of disability at two years, using the Expanded Disability Status Scale (EDSS), is a significant predictor ...
read more Sun Oct 2007
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions In Patients Receiving Interferon Beta Therapy
Categorie : Multiple SclerosisBiogen Idec Inc. (Nasdaq: BIIB) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta therapy in patients with active relapsing multiple sclerosis ( ...
read more Sun Oct 2007
Study Suggests FTY720 May Repair MS Damage By Direct Effect On Brain
Categorie : Multiple SclerosisFTY720 (fingolimod), an oral sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis (MS), acts directly on the central nervous system (CNS) to reduce disease severity in addition to peripheral effects on the immune system, according to results from a model of the dis ...
read more Sun Oct 2007
Potential New Diagnositc For Multiple Sclerosis From Simple Eye Scan
Categorie : Multiple SclerosisA five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis, potentially complementing costly magnetic resonance imaging to detect brain shrinkage -- a characteristic of the disease's progression. [ ...
read more Sun Oct 2007
Top-Line Efficacy Data Presented From Phase 2 Trial Of Alemtuzumab In Multiple Sclerosis
Categorie : Multiple SclerosisGenzyme Corporation (Nasdaq: GENZ) announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee ...
read more Sun Oct 2007
Biogen Idec And Elan Provide Update On Utilization And Safety Of TYSABRI® In Patients With Multiple Sclerosis
Categorie : Multiple SclerosisBiogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced new data on the global utilization and safety of TYSABRI® (natalizumab), citing that as of the end of September 2007 approximately 17,000 patients are on commercial and clinical therapy worldwide, and that the safet ...
read more Sun Oct 2007
Genzyme And Bayer Schering To Present New Data On Alemtuzumab In Multiple Sclerosis At ECTRIMS
Categorie : Multiple SclerosisGenzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of the European Committee for Treatment and Research in Multipl ...
read more Sun Oct 2007
Custom Search
